SEC Form 4 · accession 0001209191-15-078176
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Oct 30, 2015
Accepted (ET)
Nov 3, 2015 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 30, 2015 | S | 1,600 | $123.34 | D | 248,448 | D | |
| Common StockF2,F4 | Oct 30, 2015 | S | 1,400 | $124.33 | D | 247,048 | D | |
| Common StockF2,F5 | Oct 30, 2015 | S | 4,800 | $125.35 | D | 242,248 | D | |
| Common StockF2,F6 | Oct 30, 2015 | S | 8,125 | $126.31 | D | 234,123 | D | |
| Common StockF2,F7 | Oct 30, 2015 | S | 200 | $126.86 | D | 233,923 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- F2Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $123.34 (range $122.82 to $123.79).
- F4Open market sales reported on this line occurred at a weighted average price of $124.33 (range $123.83 to $124.74).
- F5Open market sales reported on this line occurred at a weighted average price of $125.35 (range $124.85 to $125.84).
- F6Open market sales reported on this line occurred at a weighted average price of $126.31 (range $125.85 to $126.81).
- F7Open market sales reported on this line occurred at a weighted average price of $126.86 (range $126.85 to $126.87).